Short answer
Neuronetics, Inc. (STIM) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $42M (up 9.1% year over year) with net income of −$3M.
Q2 2026 key financials · XBRL
- Revenue
- $42M
- +9.1% YoY · +20.6% QoQ
- Net income
- −$3M
- +66.0% YoY · +68.1% QoQ
- Operating margin
- -3.6%
- Gross margin
- 51.1%
- EPS (diluted)
- −$0.04
- +73.3% YoY · +75.0% QoQ
Source: XBRL data from the Neuronetics, Inc. (STIM) Q2 2026 10-Q on SEC EDGAR. USD.
Neuronetics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $41.6M, up $3.5M or 9% YoY from $38.1M
- Greenbrook strongest segment, 65% of quarterly revenue versus NeuroStar at 35%
- Net loss $3.5M versus $9.8M YoY
- Six-month net loss $14.2M versus $22.5M YoY
- Management expects clinic revenue to increase in 2026; macroeconomic pressures remain headwinds
Risk Factors
- No material changes identified; filing refers readers to 10-K filed March 17, 2026 and 10-Q filed May 5, 2026
- Credit risk carried forward through Credit Agreement and Guaranty with Perceptive Credit Holdings IV, LP
- Financing risk heightened by Credit Agreement Amendment No. 5 and Waiver dated March 12, 2026
- Management continuity risk following executive separation agreement dated July 17, 2026
- Compensation and retention risk following adoption of 2026 Equity Incentive Plan
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Neuronetics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.